These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

319 related articles for article (PubMed ID: 21519356)

  • 1. Heart rate: a forgotten link in coronary artery disease?
    Fox KM; Ferrari R
    Nat Rev Cardiol; 2011 Apr; 8(7):369-79. PubMed ID: 21519356
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Heart rate and cardiovascular protection.
    Caetano J; Delgado Alves J
    Eur J Intern Med; 2015 May; 26(4):217-22. PubMed ID: 25704330
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ivabradine in chronic stable angina: Effects by and beyond heart rate reduction.
    Camici PG; Gloekler S; Levy BI; Skalidis E; Tagliamonte E; Vardas P; Heusch G
    Int J Cardiol; 2016 Jul; 215():1-6. PubMed ID: 27104917
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Heart rate in ischemic heart disease. The innovation of ivabradine: more than pure heart rate reduction.
    Rosano GM; Vitale C; Volterrani M
    Adv Ther; 2010 Apr; 27(4):202-10. PubMed ID: 20495895
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ivabradine: the hope for a good treatment of ischemic heart disease.
    Riccioni G
    Curr Med Chem; 2013; 20(14):1817-23. PubMed ID: 23394554
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ivabradine for Treatment of Coronary Artery Disease: From Last Chance Resort to Mainstem of a Reasoned Therapy.
    Lupi A; Rognoni A; Cavallino C; Secco GG; Rosso R; Bongo AS
    Cardiovasc Hematol Agents Med Chem; 2015; 13(1):4-9. PubMed ID: 25544120
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ivabradine: beyond heart rate control.
    Riccioni G; Vitulano N; D'Orazio N
    Adv Ther; 2009 Jan; 26(1):12-24. PubMed ID: 19165437
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Selective Heart Rate Reduction With Ivabradine Increases Central Blood Pressure in Stable Coronary Artery Disease.
    Rimoldi SF; Messerli FH; Cerny D; Gloekler S; Traupe T; Laurent S; Seiler C
    Hypertension; 2016 Jun; 67(6):1205-10. PubMed ID: 27091900
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Stable coronary artery disease: are there therapeutic benefits of heart rate lowering?
    Tanna MS; Messerli FH; Bangalore S
    J Hypertens; 2019 Jun; 37(6):1112-1118. PubMed ID: 30676481
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of ivabradine on left ventricular remodelling after reperfused myocardial infarction: A pilot study.
    Gerbaud E; Montaudon M; Chasseriaud W; Gilbert S; Cochet H; Pucheu Y; Horovitz A; Bonnet J; Douard H; Coste P
    Arch Cardiovasc Dis; 2014 Jan; 107(1):33-41. PubMed ID: 24440004
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Heart rate as a treatable cardiovascular risk factor.
    Tardif JC
    Br Med Bull; 2009; 90():71-84. PubMed ID: 19474056
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of Ivabradine on Central Aortic Blood Pressure and Myocardial Perfusion in Patients With Stable Coronary Artery Disease.
    Dillinger JG; Maher V; Vitale C; Henry P; Logeart D; Manzo Silberman S; Allée G; Levy BI
    Hypertension; 2015 Dec; 66(6):1138-44. PubMed ID: 26418022
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Meta-analysis of Ivabradine in Patients With Stable Coronary Artery Disease With and Without Left Ventricular Dysfunction.
    Cammarano C; Silva M; Comee M; Donovan JL; Malloy MJ
    Clin Ther; 2016 Feb; 38(2):387-95. PubMed ID: 26839043
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ivabradine in stable coronary artery disease without clinical heart failure.
    Fox K; Ford I; Steg PG; Tardif JC; Tendera M; Ferrari R;
    N Engl J Med; 2014 Sep; 371(12):1091-9. PubMed ID: 25176136
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial.
    Fox K; Ford I; Steg PG; Tendera M; Ferrari R;
    Lancet; 2008 Sep; 372(9641):807-16. PubMed ID: 18757088
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical perspectives of heart rate slowing for coronary event reduction and heart failure.
    Danchin N; Kadri Z
    Adv Cardiol; 2006; 43():45-53. PubMed ID: 16936471
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Heart rate lowering by specific and selective I(f) current inhibition with ivabradine: a new therapeutic perspective in cardiovascular disease.
    DiFrancesco D; Camm JA
    Drugs; 2004; 64(16):1757-65. PubMed ID: 15301560
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Heart rate slowing versus other pharmacological antianginal strategies.
    Diaz A; Tardif JC
    Adv Cardiol; 2006; 43():65-78. PubMed ID: 16936473
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Heart rate reduction as a therapeutic strategy: novel options].
    Hoppe UC
    Internist (Berl); 2006 Dec; 47(12):1289-93. PubMed ID: 17077980
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Selective and specific I(f) inhibition with ivabradine: new perspectives for the treatment of cardiovascular disease.
    Ferrari R; Ceconi C
    Expert Rev Cardiovasc Ther; 2011 Aug; 9(8):959-73. PubMed ID: 21878041
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.